Photo taken from Manni Mohyuddin/X
Jan 30, 2024, 15:51
Manni Mohyuddin: It is often well known that the control arm is inferior prior to a single patient being enrolled on trial!
Manni Mohyuddin, Assistant Professor at the Huntsman Cancer Institute, University of Utah, shared on X/Twitter:
“A common excuse for poor control arms is that they were valid at the time the trial enrolled. We have shown in The Lancet Haematology, that it is often well known that the control arm is inferior prior to a single patient being enrolled on trial!”
View more information.
Source: Manni Mohyuddin/X
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 1, 2025, 19:09
Apr 1, 2025, 18:48
Apr 1, 2025, 18:37
Apr 1, 2025, 18:26
Apr 1, 2025, 18:22